130 related articles for article (PubMed ID: 22101789)
1. GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility.
Miri M; Hemati S; Safari F; Tavassoli M
Med Oncol; 2012 Sep; 29(3):1581-5. PubMed ID: 22101789
[TBL] [Abstract][Full Text] [Related]
2. eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development.
Malta-Vacas J; Chauvin C; Gonçalves L; Nazaré A; Carvalho C; Monteiro C; Bagrel D; Jean-Jean O; Brito M
Oncol Rep; 2009 Jun; 21(6):1551-8. PubMed ID: 19424636
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of GSPT1 GGCn alleles in cancer.
Malta-Vacas J; Ferreira P; Monteiro C; Brito M
Cancer Genet Cytogenet; 2009 Dec; 195(2):132-42. PubMed ID: 19963113
[TBL] [Abstract][Full Text] [Related]
4. Studies on human eRF3-PABP interaction reveal the influence of eRF3a N-terminal glycin repeat on eRF3-PABP binding affinity and the lower affinity of eRF3a 12-GGC allele involved in cancer susceptibility.
Jerbi S; Jolles B; Bouceba T; Jean-Jean O
RNA Biol; 2016; 13(3):306-15. PubMed ID: 26818177
[TBL] [Abstract][Full Text] [Related]
5. Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility.
Brito M; Malta-Vacas J; Carmona B; Aires C; Costa P; Martins AP; Ramos S; Conde AR; Monteiro C
Carcinogenesis; 2005 Dec; 26(12):2046-9. PubMed ID: 15987717
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against human translation termination factor eRF3 and their utilization for sub-cellular localization of eRF3.
Delage MM; Dutertre S; Le Guével R; Frolova L; Berkova N
J Biochem; 2011 Jul; 150(1):49-59. PubMed ID: 21421683
[TBL] [Abstract][Full Text] [Related]
7. Role of
Liu W; Ma N; Gao X; Liu W; Jia J; Tang L; Li M; Yang L; Li T; Yan L; Zhang X; Yu F
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30867251
[No Abstract] [Full Text] [Related]
8. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
[TBL] [Abstract][Full Text] [Related]
9. Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway.
Chauvin C; Salhi S; Jean-Jean O
Mol Cell Biol; 2007 Aug; 27(16):5619-29. PubMed ID: 17562865
[TBL] [Abstract][Full Text] [Related]
10. Evolution of translation termination factor eRF3: is GSPT2 generated by retrotransposition of GSPT1's mRNA?
Zhouravleva G; Schepachev V; Petrova A; Tarasov O; Inge-Vechtomov S
IUBMB Life; 2006 Apr; 58(4):199-202. PubMed ID: 16754297
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types.
Malta-Vacas J; Aires C; Costa P; Conde AR; Ramos S; Martins AP; Monteiro C; Brito M
J Clin Pathol; 2005 Jun; 58(6):621-5. PubMed ID: 15917414
[TBL] [Abstract][Full Text] [Related]
12. Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation.
Chauvin C; Salhi S; Le Goff C; Viranaicken W; Diop D; Jean-Jean O
Mol Cell Biol; 2005 Jul; 25(14):5801-11. PubMed ID: 15987998
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in genes involved in breast cancer among Iranian patients.
Farnoosh G; Saeedi-Boroujeni A; Jalali A; Keikhaei B; Mahmoudian-Sani MR
Per Med; 2021 Mar; 18(2):153-169. PubMed ID: 33565318
[TBL] [Abstract][Full Text] [Related]
14. The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study.
Yadav P; Mir R; Nandi K; Javid J; Masroor M; Ahmad I; Zuberi M; Kaza R; Jain S; Khurana N; Ray PC; Saxena A
Asian Pac J Cancer Prev; 2016; 17(3):1215-9. PubMed ID: 27039751
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of translation termination factor eRF3A and nonsense-mediated mRNA decay factor UPF1 on the expression of uORF carrying mRNAs and ribosome protein genes.
Aliouat A; Hatin I; Bertin P; François P; Stierlé V; Namy O; Salhi S; Jean-Jean O
RNA Biol; 2020 Feb; 17(2):227-239. PubMed ID: 31619139
[TBL] [Abstract][Full Text] [Related]
16. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
[TBL] [Abstract][Full Text] [Related]
17. [Identification of a novel termination release factor eRF3b expressing the eRF3 activity in vitro and in vivo].
Jakobsen CG; Segaard TM; Jean-Jean O; Frolova L; Justesen J
Mol Biol (Mosk); 2001; 35(4):672-81. PubMed ID: 11524954
[TBL] [Abstract][Full Text] [Related]
18. GGC and StuI polymorphism on the androgen receptor gene in endometrial cancer patients.
Sasaki M; Karube A; Karube Y; Watari M; Sakuragi N; Fujimoto S; Dahiya R
Biochem Biophys Res Commun; 2005 Apr; 329(1):100-4. PubMed ID: 15721279
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal degradation of human release factor eRF3a regulates translation termination complex formation.
Chauvin C; Jean-Jean O
RNA; 2008 Feb; 14(2):240-5. PubMed ID: 18083835
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic variant Ser128Arg of E-Selectin is associated with breast cancer risk and high grade tumors.
Naidu R; Har YC; Taib NA
Onkologie; 2011; 34(11):592-7. PubMed ID: 22104155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
